Pricing Log in Create free account

DiaMedica Therapeutics, Inc. (DMAC) vs Gyre Therapeutics, Inc. (GYRE)

DiaMedica Therapeutics, Inc. and Gyre Therapeutics, Inc. are both Biotechnology companies. DiaMedica Therapeutics, Inc. and Gyre Therapeutics, Inc. are of similar size ($520.4M and $493.1M). DiaMedica Therapeutics, Inc. has the higher net margin (0.00% vs −21.5%) and the higher return on invested capital (0.00% vs −8.51%). Across the 12 metrics below, Gyre Therapeutics, Inc. leads on 7 and DiaMedica Therapeutics, Inc. on 5.

Valuation

Metric DMAC GYRE Biotechnology median
P/E n/m n/m 10.85
P/S n/m 4.05 9.49
P/B 13.55 3.41 2.18
Price to free cash flow n/m n/m 25.85
EV/EBITDA n/m n/m 0.70
EV/Sales n/m 3.48 8.99
Earnings yield (7.47%) (6.03%) (31.76%)
Free cash flow yield (6.07%) (5.15%) (21.84%)

Profitability

Metric DMAC GYRE Biotechnology median
Gross margin 0.00% 91.71% 68.51%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% (21.46%) 0.00%
Free cash flow margin 0.00% (19.94%) 0.00%
Return on equity (114.62%) (18.54%) (50.82%)
Return on assets (98.18%) (14.49%) (46.04%)
Return on invested capital 0.00% (8.51%) 0.00%

Growth

Metric DMAC GYRE Biotechnology median
Revenue growth (TTM) — 13.51% 6.96%
EPS growth (last fiscal year) (16.67%) (60.00%) 29.88%
Revenue growth, 5-year CAGR — 40.96% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric DMAC GYRE Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 6.72 4.32 4.84
Net debt to EBITDA 1.70 (3.74) 1.01

Dividend

Metric DMAC GYRE Biotechnology median
Dividend yield — — 0.40%
Payout ratio — — —

Size

Metric DMAC GYRE Biotechnology median
Market cap 520.38m 493.06m 163.56m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack